Lichen planus is a common inflammatory (swelling and pain of tissue) disease in the general population that affects mostly the mouth although skin and genital areas can also be affected. It can cause considerable discomfort during activities such as eating, talking and tooth brushing and may impair sexual function with an overall deleterious impact on quality of life. There is also increased evidence of cancer in a subtype of lichen planus. Therefore, treatment is essential in these patients to control the symptoms and improve the quality of life. Locally applied steroids are the first line medicines used in the treatment of patients with lichen planus. This medicine can only control the symptoms, but cannot cure the disease. In addition, this treatment cannot be effective in all patients with lichen planus. This may be attributed to differences in host factors, mouth bacteria and individual host responses to bacteria. The exact cause of this disease is also unknown. New studies have shown changes in the balance of mouth bacteria and host responses to bacteria in patients with lichen planus. So the main purpose of our study is to identify clinical(age, gender, related medical conditions, oral health and the presence of deleterious habits like smoking and alcohol consumption), molecular(analysis of oral microbes and immune markers) and histological factors (change within tissue) associated with poor response in lichen planus patients undergoing treatment with locally applied steroid medicines. Overall, knowledge of these factors associated with disease progression is sparse, which limits progress in the realm of development of novel and personalised treatment strategies. In this study, we explore the individual and combined role of different markers in lichen planus for improving diagnosis, predicting disease progression and treatment effectiveness.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Identification of host related factors associated with poor response to topical steroid therapy in patients with lichen planus.
Timeframe: change in disease severity score of lichen planus from baseline (start of topical steroid treatment) to completion of topical steroid therapy( 2 months after the first visit)
Identification of inflammatory/immune markers associated with poor response to topical steroid therapy in patients with lichen planus.
Timeframe: change in disease severity score of lichen planus from baseline (start of topical steroid treatment) to completion of topical steroid therapy( 2 months after the first visit)
Determination of microbiome characteristics predictive of response to treatment.
Timeframe: change in disease severity score of lichen planus from baseline (start of topical steroid treatment) to completion of topical steroid therapy( 2 months after the first visit)
Identification of histopathological morphological markers associated with poor response to topical steroid therapy in patients with lichen planus.
Timeframe: change in disease severity score of lichen planus from baseline (start of topical steroid treatment) to completion of topical steroid therapy( 2 months after the first visit)